These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36863926)

  • 21. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant.
    Di Tommaso A; Saletti G; Pizza M; Rappuoli R; Dougan G; Abrignani S; Douce G; De Magistris MT
    Infect Immun; 1996 Mar; 64(3):974-9. PubMed ID: 8641809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.
    Watanabe I; Ross TM; Tamura S; Ichinohe T; Ito S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
    Vaccine; 2003 Nov; 21(31):4532-8. PubMed ID: 14575764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
    Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
    Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.
    Kayamuro H; Yoshioka Y; Abe Y; Arita S; Katayama K; Nomura T; Yoshikawa T; Kubota-Koketsu R; Ikuta K; Okamoto S; Mori Y; Kunisawa J; Kiyono H; Itoh N; Nagano K; Kamada H; Tsutsumi Y; Tsunoda S
    J Virol; 2010 Dec; 84(24):12703-12. PubMed ID: 20881038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.
    Xu W; Shen Y; Jiang Z; Wang Y; Chu Y; Xiong S
    Vaccine; 2004 Sep; 22(27-28):3603-12. PubMed ID: 15315839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal and sublingual delivery of inactivated polio vaccine.
    Kraan H; Soema P; Amorij JP; Kersten G
    Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal acellular pertussis vaccine provides mucosal immunity and protects mice from
    Boehm DT; Wolf MA; Hall JM; Wong TY; Sen-Kilic E; Basinger HD; Dziadowicz SA; Gutierrez MP; Blackwood CB; Bradford SD; Begley KA; Witt WT; Varney ME; Barbier M; Damron FH
    NPJ Vaccines; 2019; 4():40. PubMed ID: 31602318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus.
    Wang X; Zhang X; Kang Y; Jin H; Du X; Zhao G; Yu Y; Li J; Su B; Huang C; Wang B
    Vaccine; 2008 Sep; 26(40):5135-44. PubMed ID: 18462848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal co-administration of 1,8-cineole with influenza vaccine provide cross-protection against influenza virus infection.
    Li Y; Xu YL; Lai YN; Liao SH; Liu N; Xu PP
    Phytomedicine; 2017 Oct; 34():127-135. PubMed ID: 28899494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.
    Gallorini S; Taccone M; Bonci A; Nardelli F; Casini D; Bonificio A; Kommareddy S; Bertholet S; O'Hagan DT; Baudner BC
    Vaccine; 2014 Apr; 32(20):2382-8. PubMed ID: 24434044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
    Fan X; Yue Y; Xiong S
    Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice.
    Shahiwala A; Amiji MM
    J Drug Target; 2008 May; 16(4):302-10. PubMed ID: 18446609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.
    Liu H; Patil HP; de Vries-Idema J; Wilschut J; Huckriede A
    PLoS One; 2013; 8(7):e69649. PubMed ID: 23936066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.
    Verma V; Tan W; Puth S; Cho KO; Lee SE; Rhee JH
    J Transl Med; 2016 May; 14(1):135. PubMed ID: 27184355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection.
    Kim YI; Song JH; Kwon BE; Kim HN; Seo MD; Park K; Lee S; Yeo SG; Kweon MN; Ko HJ; Chang SY
    Vaccine; 2015 Nov; 33(48):6604-10. PubMed ID: 26529069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases.
    Fujimoto K; Kawaguchi Y; Shimohigoshi M; Gotoh Y; Nakano Y; Usui Y; Hayashi T; Kimura Y; Uematsu M; Yamamoto T; Akeda Y; Rhee JH; Yuki Y; Ishii KJ; Crowe SE; Ernst PB; Kiyono H; Uematsu S
    Gastroenterology; 2019 Dec; 157(6):1530-1543.e4. PubMed ID: 31445037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.